Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Goldschmidt, Hartmut [VerfasserIn]   i
 Salwender, Hans [VerfasserIn]   i
 Egerer, Gerlinde [VerfasserIn]   i
 Kempe, Rudolf [VerfasserIn]   i
 Voigt, Thor [VerfasserIn]   i
Titel:Comparison of oral itasetron with oral ondansetron
Titelzusatz:results of a double-blind, active-controlled phase II study in chemotherapy-naive patients receiving moderately emetogenic chemotherapy
Verf.angabe:Hartmut Goldschmidt, Hans Salwender, Gerlinde Egerer, Rudolf Kempe, Thor Voigt
E-Jahr:1997
Jahr:June 1997
Umfang:9 S.
Fussnoten:Gesehen am 24.04.2025
Titel Quelle:Enthalten in: Anti-cancer drugs
Ort Quelle:Hagerstown, Md. : Lippincott Williams & Wilkins, 1990
Jahr Quelle:1997
Band/Heft Quelle:8(1997), 5, Seite 436-444
ISSN Quelle:1473-5741
Abstract:Itasetron hydrochloride is a new 5-hydroxytryptamine3 (5-HT3) antagonist. Experimental Investigations show that orally it is rapidly absorbed (about 90 min), is highly bioavailable (greater than 90%), has a long half-life (about 12 h) and is more potent (about 10 times) in animal models than ondansetron, currently standard therapy for the prophylactic control of chemotherapy induced nausea and vomiting. This paper describes the results of a study designed to assess the efficacy and tolerability of five (0.5, 1, 2, 4 and 8 mg) twice-daily doses of itasetron hydrochloride, in comparison with 8 mg b.i.d. ondansetron. Assessments were made in patients (n = 104) with histologically confirmed cancer (excluding head and neck tumors) and about to receive their first course of moderately emetogenic chemotherapy. Itasetron hydrochloride demonstrated comparable efficacy to ondansetron; no statistically significant between-group differences were observed in the primary (complete response rate) or secondary (nausea and delayed emesis) efficacy criteria. Adverse events were similar in type and incidence across all treatment groups, and were those expected for this therapeutic class. The tolerability of itasetron hydrochloride was assessed as ‘very good’ or ‘rather good’ by 81% of patients and 89% of physicians. In conclusion, itasetron hydrochloride is effective and well tolerated in patients receiving moderately emetogenic chemotherapy. Oral doses of 1 mg b.l.d. or above will be used in further clinical studies.
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Volltext: https://journals.lww.com/anti-cancerdrugs/abstract/1997/06000/comparison_of_oral_itasetron_with_oral.4.aspx
Datenträger:Online-Ressource
Sprache:eng
K10plus-PPN:1923558080
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/69338668   QR-Code
zum Seitenanfang